With a strong background in technology and healthcare investments, the fund manager has executed over 50 successful deals across North America and Europe. Their operator-first approach emphasizes collaboration with portfolio companies to drive growth. Noteworthy exits in the biotech sector showcase their ability to identify and capitalize on emerging trends. Their strategic focus on early to growth-stage investments highlights a commitment to fostering innovation while securing long-term returns.